~~<i id='221224F999'><strike id='221224F999'><tt id='221224F999'><pre id='221224F999'></pre></tt></strike></i>~~

Home» comprehensive» explore

explore

author：Wikipedia 2025-10-01 18:08:44 Page View：127

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Pfizer highlights cancer drugs it thinks could reignite investor interest
Next article： Medicare details structure of new drug price negotiation program

explore

Jerome Adams on the need for new antivirals for Covid

PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

1:16FormerPresidentandRepublicanpresidentialcandidateDonaldTrumpreactsasheholdsacampaignrallyinErie,

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

1:19Ademonstratorrunsonthethirdnightofprotestssparkedbythefatalpoliceshootingofa17-year-olddriverint

TytoCare raises $49 million to build out AI

AdobeYou’rereadingthewebeditionofSTATHealthTech,ourguidetohowtechistransformingthelifesciences. Sign